{
    "clinical_study": {
        "@rank": "64043", 
        "arm_group": [
            {
                "arm_group_label": "Chemotherapy followed by surgery", 
                "arm_group_type": "Experimental", 
                "description": "neoadjuvant chemotherapy (Cisplatin) followed by surgery (radial hysterectomy)"
            }, 
            {
                "arm_group_label": "Radio-chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Concomitant radiotherapy (external radiotherapy combined with external boost or brachytherapy) and chemotherapy (cisplatin)"
            }
        ], 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor\n      so that it can be removed during surgery. Radiation therapy uses high-energy x-rays to kill\n      tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. It is\n      not yet known whether chemotherapy is more effective followed by surgery or combined with\n      radiation therapy in treating cervical cancer.\n\n      PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy followed by\n      radical hysterectomy with that of chemotherapy plus radiation therapy in treating patients\n      who have stage IB or stage II cervical cancer."
        }, 
        "brief_title": "Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical Cancer", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Compare the overall and progression-free survival of patients with stage IB2, IIA, or\n           IIB cervical cancer treated with neoadjuvant cisplatin-based chemotherapy followed by\n           radical hysterectomy vs standard therapy comprising concurrent radiotherapy and\n           cisplatin-based chemotherapy.\n\n        -  Compare the toxicity of these regimens in these patients.\n\n        -  Compare the quality of life of patients treated with these regimens.\n\n      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to\n      participating center, FIGO stage, age (18 to 50 vs 51 to 75), and histological subtype\n      (adenomatous vs non-adenomatous component). Patients are randomized to 1 of 2 treatment\n      arms.\n\n        -  Arm I: Patients receive neoadjuvant cisplatin-based chemotherapy on day 1. Treatment\n           repeats every 21 days. Within 6 weeks after the last chemotherapy course, patients\n           undergo a type III-V Piver-Rutledge radical hysterectomy. Patients with positive lymph\n           nodes or tumor invasion into the parametria or less than 5 mm from the resection\n           borders after surgery receive standard adjuvant external beam radiotherapy once daily,\n           5 days a week, for 5-5.6 weeks (25-28 treatment days) followed by external boost\n           radiotherapy or brachytherapy for 1 or 2 days.\n\n        -  Arm II: Patients receive standard therapy comprising radiotherapy as in arm I\n           concurrently with cisplatin-based chemotherapy once weekly for 6 weeks. Adjuvant\n           hysterectomy is allowed, but not recommended, in case of histologically proven residual\n           tumor.\n\n      Treatment in both arms continues in the absence of disease progression or unacceptable\n      toxicity. For patients in both arms, cisplatin may be combined with other chemotherapeutics\n      as long as the minimum platinum dose is given.\n\n      Quality of life is assessed at baseline and at 6, 12, 18, and 24 months.\n\n      Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then\n      annually thereafter.\n\n      PROJECTED ACCRUAL: A total of 686 patients (343 per treatment arm) will be accrued for this\n      study within 3.8 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed cervical cancer, including the following subtypes:\n\n               -  Squamous cell carcinoma\n\n               -  Adenosquamous cell carcinoma\n\n               -  Adenocarcinoma (excluding small cell, clear cell, and other rare variants of the\n                  classical adenocarcinoma)\n\n          -  FIGO stage IB2, IIA (greater than 4 cm), or IIB\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 to 75\n\n        Performance status:\n\n          -  WHO 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count greater than 1,500/mm^3\n\n          -  Platelet count greater than 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin less than 1.46 mg/dL\n\n        Renal:\n\n          -  Creatinine clearance greater than 60 mL/min\n\n        Other:\n\n          -  No other prior or concurrent malignancy except adequately treated basal cell skin\n             cancer\n\n          -  No psychological, familial, sociological, or geographical condition that would\n             preclude study\n\n          -  Not pregnant\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  No prior chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  No prior radiotherapy\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  No other concurrent anticancer agent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "686", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 6, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00039338", 
            "org_study_id": "EORTC-55994", 
            "secondary_id": "2008-003396-52"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chemotherapy followed by surgery", 
                "description": "Radial hysterectomy", 
                "intervention_name": "conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Chemotherapy followed by surgery", 
                    "Radio-chemotherapy"
                ], 
                "description": "Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.", 
                "intervention_name": "neoadjuvant chemotherapy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Radio-chemotherapy", 
                "description": "Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.", 
                "intervention_name": "brachytherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Radio-chemotherapy", 
                "description": "Between 45-50 Gy, in fractions of 1.8 to 2 Gy.", 
                "intervention_name": "radiation therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "Chemotherapy followed by surgery", 
                    "Radio-chemotherapy"
                ], 
                "description": "Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cisplatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stage IB cervical cancer", 
            "stage IIB cervical cancer", 
            "stage IIA cervical cancer", 
            "cervical squamous cell carcinoma", 
            "cervical adenocarcinoma", 
            "cervical adenosquamous cell carcinoma"
        ], 
        "lastchanged_date": "August 26, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-55994"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria"
                    }, 
                    "name": "Karl-Franzens-University Graz"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria"
                    }, 
                    "name": "Kaiser Franz Josef Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium"
                    }, 
                    "name": "Universitair Ziekenhuis Antwerpen"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }, 
                    "name": "U.Z. Gasthuisberg"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "Centre Hospitalier Regional de la Citadelle"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France"
                    }, 
                    "name": "Centre Regional Francois Baclesse"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Europeo Di Oncologia"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monza", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale San Gerardo"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Naples", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Nazionale Per Lo Studio E La Cura Dei Tumori"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "zip": "10128"
                    }, 
                    "name": "Ospedale Mauriziano Umberto I"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turin", 
                        "country": "Italy", 
                        "zip": "10126"
                    }, 
                    "name": "Clinica Universitaria"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varese", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale di Circolo e Fondazione Macchi"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105 AZ"
                    }, 
                    "name": "Academisch Medisch Centrum at University of Amsterdam"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Vrije Universiteit Medisch Centrum"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Enschede", 
                        "country": "Netherlands"
                    }, 
                    "name": "Medisch Spectrum Twente"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leiden", 
                        "country": "Netherlands"
                    }, 
                    "name": "Leiden University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands"
                    }, 
                    "name": "Universitair Medisch Centrum St. Radboud - Nijmegen"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3008 AE"
                    }, 
                    "name": "Erasmus MC - Daniel den Hoed Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands"
                    }, 
                    "name": "Universitair Medisch Centrum - Academisch Ziekenhuis"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coimbra", 
                        "country": "Portugal"
                    }, 
                    "name": "Hospitais da Universidade de Coimbra (HUC)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario San Carlos"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Margate", 
                        "country": "United Kingdom", 
                        "state": "England"
                    }, 
                    "name": "Queen Elizabeth The Queen Mother Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "state": "Scotland"
                    }, 
                    "name": "NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maidstone, Kent", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Mid Kent Oncology Centre"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium", 
                "France", 
                "Italy", 
                "Netherlands", 
                "Portugal", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa>4 cm or IIb Cervical Cancer", 
        "overall_contact": {
            "email": "melanie.beauvois@eortc.be", 
            "last_name": "Melanie Beauvois", 
            "phone": "+32 2 7741687"
        }, 
        "overall_official": [
            {
                "affiliation": "Istituto Europeo Di Oncologia, Milano", 
                "last_name": "Fabio Landoni, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Ospedale Alessandro Manzoni, Lecco", 
                "last_name": "Alessandro Colombo, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Istituto Nazionale per lo Studio e la Cura dei Tumori, Napoli", 
                "last_name": "Stefano Greggi, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam", 
                "last_name": "Gemma G. Kenter, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Agency for Health and Food Safety", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Italy: AIFA: Italian Drug Agency", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Portugal: National Authority of Medicines and Health Products", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival as measured by Kaplan Meier after each course, every 3 months  for 1 year, every 6 months for 4 years, and then annually", 
            "safety_issue": "No", 
            "time_frame": "16 years from FPI"
        }, 
        "removed_countries": {
            "country": [
                "Poland", 
                "Argentina"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00039338"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival as measured by Kaplan Meier and RECIST after each course, every 3 months  for 1 year, every 6 months for 4 years, and then annually", 
                "safety_issue": "No", 
                "time_frame": "16 years from FPI"
            }, 
            {
                "measure": "Toxicity as measured by NCIC Common Toxicity Criteria v2.0 after each course", 
                "safety_issue": "Yes", 
                "time_frame": "16 years from FPI"
            }, 
            {
                "measure": "Health-related quality of life as measured by Quality of Life Questionnaire-C30 at baseline  and at 6, 12, 18, and 24 months", 
                "safety_issue": "No", 
                "time_frame": "16 years from FPI"
            }
        ], 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }, 
    "geocoordinates": {
        "Academisch Medisch Centrum at University of Amsterdam": "52.37 4.895", 
        "Centre Hospitalier Regional de la Citadelle": "50.633 5.58", 
        "Centre Regional Francois Baclesse": "49.183 -0.371", 
        "Clinica Universitaria": "45.071 7.684", 
        "Erasmus MC - Daniel den Hoed Cancer Center": "51.924 4.482", 
        "Hospitais da Universidade de Coimbra (HUC)": "40.211 -8.429", 
        "Hospital Universitario San Carlos": "40.417 -3.7", 
        "Istituto Europeo Di Oncologia": "45.464 9.188", 
        "Istituto Nazionale Per Lo Studio E La Cura Dei Tumori": "40.84 14.253", 
        "Kaiser Franz Josef Hospital": "48.208 16.374", 
        "Karl-Franzens-University Graz": "47.071 15.44", 
        "Leiden University Medical Center": "52.16 4.494", 
        "Medisch Spectrum Twente": "52.222 6.894", 
        "Mid Kent Oncology Centre": "51.27 0.523", 
        "NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre": "55.864 -4.252", 
        "Ospedale Mauriziano Umberto I": "45.071 7.684", 
        "Ospedale San Gerardo": "45.584 9.273", 
        "Ospedale di Circolo e Fondazione Macchi": "45.818 8.826", 
        "Queen Elizabeth The Queen Mother Hospital": "51.39 1.387", 
        "U.Z. Gasthuisberg": "50.878 4.704", 
        "Universitair Medisch Centrum - Academisch Ziekenhuis": "52.09 5.11", 
        "Universitair Medisch Centrum St. Radboud - Nijmegen": "51.843 5.855", 
        "Universitair Ziekenhuis Antwerpen": "51.153 4.438", 
        "Vrije Universiteit Medisch Centrum": "52.37 4.895"
    }
}